Key clinical point: Regulatory hurdles are currently stifling biosimilar adoption.
Major finding: Industry stakeholders have yet to recognize the value biosimilars bring.
Study details: An expert presentation on status of the biosimilar market in the United States.
Disclosures: Ms. Woollett disclosed no conflicts of interest relevant to her presentation.
Woollet G et al. AMCP NEXUS 2019, Session D4.